TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01851759
Drug: cinepazide
Normalized name: cinepazide
DrugBank: Cinepazide (DB12123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 branches of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.~1 branch of simulation agent of Methanesulfonic acid cinepazide injection was matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.
Study: NCT04027309
Drug: Gilteritinib
Normalized name: Gilteritinib
DrugBank: Gilteritinib (DB12141)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients with a FLT3 mutation w ill be randomized to receive either the investigational drug gilteritinib or midostaurin given sequentially to standard induction and consolidation chemotherapy. After completing induction and consolidation treatment, patients who achieve CR/CRi/MLFS will receive maintenance therapy with gilteritinib or midostaurin
Study: NCT04004975
Drug: Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib is a multitarget receptor tyrosine kinase inhibitor which inhibits vascular endothelial growth factor receptor (VEGFR) 1-3, fibroblast growth factor receptor (FGFR) 1-4, platelet-derived growth factor receptors (PDGFR) α/β, c-Kit, and Met.
Study: NCT01716442
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Per dose: Rituximab 375 mg/m2 (max.500mg/day). efficacy monitored by CD19 cell count. If CD19 cells are not depleted, second or third doses are given at 2-3 weeks interval.
Study: NCT02304770
Drug: Aminolaevulinic acid photodynamic therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
DrugBank: Laevulinic Acid (DB02239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminolaevulinic acid mediated photodynamic therapy
Study: NCT03198507
Drug: Active Comparator
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intended dose of the Active Comparator (250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, equivalent to a total daily dose of:~* Amoxicillin 3000 mg~* Omeprazole 120 mg~One 50mg Riboflavin tablet to be taken once daily to maintain the blind.
Study: NCT00343460
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV and orally
Study: NCT00343460
Drug: Palonosetron Hydrochloride
Normalized name: Palonosetron Hydrochloride
DrugBank: Palonosetron (DB00377)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT03805152
Drug: Dysport (R)
Normalized name: Dysport
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Intramuscular injection
Study: NCT00700115
Drug: Kaletra + Isentress
DrugBank: Kale (DB14564)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kaletra 400/100 mg + Isentress 400 mg BID
Study: NCT00835861
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Women randomized to the Experimental arm will receive standard diet and glucose self-monitoring education. They will be initiated on Metformin 500 BID if they were medication naïve, or will be continued on their current dosage of Metformin if they were taking it prior to pregnancy. At each clinic visit fasting and one hour post prandial glucose values will be reviewed, and dosage will be titrated to a maximum of 2250mg/day to achieve target glycemic control. If glycemic control can not be achieved with Metformin as a single agent insulin will be added.
Study: NCT04320316
Drug: Crysvita (burosumab-twza) Treatment
Normalized name: Crysvita
DrugBank: Burosumab (DB14012)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: KRN23 is a fully human IgG1monoclonal antibody that binds to and inhibits the activity of FGF23, leading to an increase in serum phosphorus levels. It is a potential therapeutic candidate for the treatment of XLH, Tumor-Induced Osteomalacia (TIO), and the rickets/osteomalacia resulting from Epidermal Nevus Syndrome (ENS). All of these conditions are diseases of bone hypomineralization, caused by urinary phosphate wasting due to elevated levels of FGF23.
Study: NCT01032122
Drug: rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: induction phase: 375mg/m² qw, 4wks; followed by maintenance phase: 375mg/m², every 8 wks; duration: 2 years.
Study: NCT01666041
Drug: fenofibrate/omega
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01666041
Drug: fenofibrate
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00006340
Drug: ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04027309
Drug: Midostaurin
Normalized name: Midostaurin
DrugBank: Midostaurin (DB06595)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients with a FLT3 mutation w ill be randomized to receive either the investigational drug gilteritinib or midostaurin given sequentially to standard induction and consolidation chemotherapy. After completing induction and consolidation treatment, patients who achieve CR/CRi/MLFS will receive maintenance therapy with gilteritinib or midostaurin
Study: NCT00835861
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Women randomized to the Insulin group will receive standard diet and glycemic monitoring education. They will be initiated on weight based Regular and NPH insulin at a total dosage of 0.7units/kg in the first trimester or 0.8units/kg in the second trimester divided as 2/3 of the total dosage (with 2/3 given as NPH and 1/3 given as Regular) administered before breakfast and 1/3 of the total dosage (with 1/2 given as NPH and 1/2 given as Regular)administered with dinner. At each clinic visit fasting and one hour post prandial glucose values will be reviewed, and dosage will be titrated to achieve optimal glycemic control with fasting values \<90 and one hour post prandial values \<130.
Study: NCT00971815
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: first week: 10mg/day. Then, treatment with 20mg/day is continued throughout a 3 months period of time.
Study: NCT00261261
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00503815
Drug: Polyethylene glycol 3350 based bowel preparation
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03588884
Drug: Calcifediol Oral Capsule
Normalized name: calcifediol Oral Capsule
DrugBank: Calcifediol (DB00146)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsule, daily
Study: NCT03588884
Drug: Calcifediol Oral Product
Normalized name: calcifediol Oral Product
DrugBank: Calcifediol (DB00146)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsule, once a month
Study: NCT03588884
Drug: Cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, once a month
Study: NCT03588884
Drug: Paricalcitol Oral Capsule
Normalized name: paricalcitol Oral Capsule
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsule, daily
Study: NCT03042819
Drug: Selinexor
Normalized name: Selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Selinexor is a Selective Inhibitor of Nuclear Export (SINE) compound that binds and inactivates Exportin 1 (XPO1), thereby forcing the nuclear retention of key tumor suppressor proteins (TSPs).
Study: NCT03444636
Drug: Ropivacaine/Fentanyl
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ropivacaine 0.2% with Fentanyl 5 µg/ml; flow rate of 0.1 ml/kg/hr
Study: NCT03444636
Drug: Bupivacaine/Fentanyl
Normalized name: BUPIVACAINE/FENTANYL
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine 0.125% with Fentanyl 5 µg/ml; flow rate of 0.1 ml/kg/hr
Study: NCT00934362
Drug: Lucinactant first
DrugBank: Lucinactant (DB04897)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lucinactant 120 mg (20 mg/ml) x 5 doses over 24 hours, then washout period x 14 days, then vehicle x 5 doses over 24 hrs
Study: NCT04223219
Drug: Dexmedetomidine, Ketamine, Magnesium sulfate
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: * Induction of anesthesia : Midazolam 2 mg, Fentanyl 3 µg/kg, propofol 50-100 mg and Atracurium 0.5 mg/kg.~* Maintenance of anesthesia (intraoperative until tracheal extubation):~Maintenance of anesthesia will be achieved by isoflurane with concentration 0.5-1.5 % with 40% oxygen. During cardiopulmonary bypass by continuous infusion of Propofol at a rate of 2 mg/kg/hr. and Atracurium at a rate of 10 g/kg/min.~* The patients will receive infusions of dexmedetomidine 0.2 µg/kg/h, ketamine 2 µg/kg/min, and magnesium sulfate 5 mg/kg/h.~* After tracheal extubation:~all the patients will receive standard analgesia (i.v. paracetamol 1 gm every 12 hours and i.v. ketorolac 30 mg every 12 hours) and morphine patient controlled analgesia with bolus dose = 2 mg, lockout interval = 10 minutes, 4-hour dose limit = 10 mg, with no background infusion.
Study: NCT03993106
Drug: sEphB4-HSA
Normalized name: SEphB4-HSA
DrugBank: SEphB4-HSA (DB14797)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sEphB-HSA may prevent tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor.
Study: NCT00528450
Drug: arsenic trioxide
Normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00528450
Drug: idarubicin
Normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03646461
Drug: Ibrutinib 560mg PO daily (Imbruvica)
Normalized name: ibrutinib 560 MG
DrugBank: Rutin (DB01698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTK inhibitor combined with PD-1 inhibitor
Study: NCT03646461
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab 400mg/m2 x 1 then 250 mg/m2 weekly 28 day cycle
Study: NCT03646461
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab 3mg/kg biweekly 28 day cycle
Study: NCT02127697
Drug: salbutamol/ albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken as rescue medication
Study: NCT00111852
Drug: Desmoteplase
Normalized name: Desmoteplase
DrugBank: Desmoteplase (DB04925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmoteplase 90 mcg/kg, intravenous administration.
Study: NCT00111852
Drug: Desmoteplase
Normalized name: Desmoteplase
DrugBank: Desmoteplase (DB04925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmoteplase 125 mcg/kg, intravenous administration.
Study: NCT02167139
Drug: Humira (adalimumab)
Normalized name: adalimumab Prefilled Syringe [Humira]
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02167139
Drug: SB5 (proposed biosimilar to adalimumab)
Normalized name: SB5+
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01516086
Drug: Fluticasone Propionate (FP)
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: FP Inhalation BID
Study: NCT04413617
Drug: PF-06650833
Normalized name: PF-06650833
DrugBank: PF-06650833 (DB15143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg
Study: NCT04413617
Drug: PF-06651600
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg
Study: NCT04413617
Drug: Tofacitinib
Normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 11 mg
Study: NCT02689362
Drug: Evogliptin
Normalized name: Evogliptin
DrugBank: Evogliptin (DB12625)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet per day
Study: NCT02689362
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 tablet per day
Study: NCT02689362
Drug: Placebo Evogliptin
DrugBank: Evogliptin (DB12625)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet per day
Study: NCT02689362
Drug: Placebo Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 tablet per day
Study: NCT01279785
Drug: 123I-MIP-1072
Normalized name: 123I-
DrugBank: 123I-iodometomidate (DB13021)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV dose
Study: NCT02681978
Drug: Ivabradine
Normalized name: Ivabradine
DrugBank: Ivabradine (DB09083)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ivabradine 5 mg twice daily
Study: NCT01280994
Drug: Hyperpolarized 129Xenon Gas
Normalized name: xenon-129, hyperpolarized
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperpolarized 129Xenon Gas will be administered in multiple doses in volumes that are tailored to the subject's total lung capacity (TLC) followed by a breath hold of up to 15 seconds. Subsequent 129Xe doses will only be administered once the subject is ready to proceed.
Study: NCT02865616
Drug: MET-2
Normalized name: Met
DrugBank: Methionine (DB00134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microbial Ecosystem Therapeutics (MET) is a new treatment approach for debilitating recurrent Clostridium difficile infection that has been developed as an alternative to fecal transplantation.
Study: NCT02865616
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be on vancomycin to control symptoms up until the time of the treatment. Patient must hold their p.o. vancomycin for 24 hours prior to receiving the first dose.
Study: NCT03937999
Drug: Bezlotoxumab
Normalized name: Bezlotoxumab
DrugBank: Bezlotoxumab (DB13140)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Injection: 1,000 mg/40 mL (25 mg/mL) solution in a single-dose vial.
Study: NCT00522808
Drug: A-831
Normalized name: Padimate A
DrugBank: Padimate A (DB11229)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04009681
Drug: THOR-707
Normalized name: IL-2 variant THOR-707
DrugBank: Pegenzileukin (DB17495)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution for intravenous (IV) administration; Route of administration: IV administration
Study: NCT04009681
Drug: Checkpoint inhibitor
Normalized name: Anti-tim3 checkpoint inhibitor mbg453
DrugBank: Sabatolimab (DB16322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution for IV administration; Route of administration: IV administration
Study: NCT04009681
Drug: anti-EGFR antibody
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form: solution for IV administration; Route of administration: IV administration
Study: NCT01771289
Drug: docetaxel/cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: weekly docetaxel/cisplatin combined with radiation
Study: NCT05890235
Drug: Tamsulosin Hydrochloride
Normalized name: Tamsulosin Hydrochloride
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamsulosin is α1A-adrenergic receptor which has used in treatment of BPH for few years. The instruction of Tamsulosin Capsule is 1 tablet at a time, 1 time a day.
Study: NCT03174457
Drug: Micafungin
Normalized name: Micafungin
DrugBank: Micafungin (DB01141)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous
Study: NCT01406327
Drug: Ambrisentan
Normalized name: Ambrisentan
DrugBank: Ambrisentan (DB06403)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ambrisentan
Study: NCT04338802
Drug: Nintedanib 150 MG
Normalized name: nintedanib 150 MG
DrugBank: Nintedanib (DB09079)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nintedanib cloth sulfonate 150 mg, twice a day, about 12 hours apart. Continuous medication for 8 weeks.
Study: NCT01377337
Drug: sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mEq/kg sodium bicarbonate administered intravenously immediately following the administration of the first epinephrine dose during advanced CPR. Dose may be repeated every 5-10 minutes up to 3 doses.~Note: The Placebo Arm receives 1 ml/Kg of 0.9% NaCl (in a blinded fashion).
Study: NCT02099955
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4000 IU/day or 2000 IU/day for 12 weeks
Study: NCT00052117
Drug: capravirine
Normalized name: Capravirine
DrugBank: Capravirine (DB08502)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00052117
Drug: Kaletra
Normalized name: Kaletra
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04150861
Drug: Follitropin Delta
Normalized name: follitropin delta
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Solution for Injection, subcutaneous administration
Study: NCT02440841
Drug: fedovapagon
Normalized name: Fedovapagon
DrugBank: Fedovapagon (DB11734)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02440841
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02440841
Drug: rifampicin
Normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02453711
Drug: semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Once-daily subcutaneous (s.c., under the skin) administration with dose escalation.
Study: NCT02453711
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Once-daily subcutaneous (s.c., under the skin) administration with dose escalation.
Study: NCT00302367
Drug: OROS methylphenidate hydrochloride
Normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00302367
Drug: immediate release methylphenidate hydrochloride
Normalized name: methylphenidate Extended Release Suspension
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04121091
Drug: Pramipexole Pill
Normalized name: pramipexole Pill
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Add-on pramipexole
Study: NCT01319994
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin 850mg TDS (12 weeks)
Study: NCT04547829
Drug: pegylated recombinant human granulocyte-colony stimulating factor
Normalized name: Glycosylated recombinant granulocyte colony stimulating factor
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dosage was determined according to the patient's weight, 100 UG / kg each time; The method of administration: subcutaneous injection; The time of administration: 24-48 hours after the end of chemotherapy, once in each chemotherapy cycle.
Study: NCT02881866
Drug: Furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02881866
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02821546
Drug: Lactated Ringer's solution
Normalized name: Lactated Ringer's Solution Intravenous Solution
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard fluid hydration with Lactated Ringer's solution is calculated based on Holiday Segar's equation Aggressive hydration with Lactated Ringer's solution is defined as administration of 150 ml/hour of fluid
Study: NCT00564876
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fresh frozen tumor tissue must be available prior to initiating dasatinib. Eligible patients will receive neoadjuvant dasatinib 70 mg PO twice daily for 3 weeks followed by surgery. The surgical specimen will be evaluated for pathologic response. The second tumor sample will be obtained after 3 weeks of dasatinib therapy at the time of definitive surgical resection which will be evaluated for changes in genomic expression profiles. Patients with at least a 15% decrease or better objective response, without evidence of progression (per tumor evaluation pre-surgery) or pathologic response (as defined as ≥30% tumor necrosis or cell death) to neoadjuvant dasatinib therapy will be eligible to receive dasatinib 70 mg twice daily for 90 days after the completion of standard adjuvant therapy.
Study: NCT04396574
Drug: Lasmiditan
Normalized name: lasmiditan
DrugBank: Lasmiditan (DB11732)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally
Study: NCT00632866
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine : 200mg / day since 24 weeks
Study: NCT02668393
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02668393
Drug: Nintedanib
Normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Low Dose
Study: NCT02668393
Drug: Nintedanib
Normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Medium dose
Study: NCT02668393
Drug: Nintedanib
Normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: High dose
Study: NCT02668393
Drug: Nintedanib
Normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Continuous high dose
Study: NCT01678495
Drug: Recombinant tissue plasminogen activator
Normalized name: Tissue plasminogen activator, recombinant
DrugBank: Plasminogen (DB16701)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00644982
Drug: sertraline
Normalized name: Sertraline
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flexibly-titrated 50 mg tablets, 50-150 mg/day and venlafaxine placebo orally for 10 weeks.
Study: NCT00644982
Drug: venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flexibly-titrated 75 mg capsules, 75-225mg/day and sertraline placebo orally for 10 weeks.
Study: NCT00063765
Drug: Ciliary Neurotrophic Factor Implant NT-501
Normalized name: brain-derived neurotrophic factor
DrugBank: Ciliary neurotrophic factor (DB05344)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02093819
Drug: BI 416970
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single rising doses
Study: NCT03323034
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03323034
Drug: Pevonedistat
Normalized name: Pevonedistat
DrugBank: Pevonedistat (DB11759)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV